» Articles » PMID: 34196841

Monogenic and Polygenic Models of Coronary Artery Disease

Overview
Publisher Current Science
Date 2021 Jul 1
PMID 34196841
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of The Review: Coronary artery disease (CAD) is a common disease globally attributable to the interplay of complex genetic and lifestyle factors. Here, we review how genomic sequencing advances have broadened the fundamental understanding of the monogenic and polygenic contributions to CAD and how these insights can be utilized, in part by creating polygenic risk estimates, for improved disease risk stratification at the individual patient level.

Recent Findings: Initial studies linking premature CAD with rare familial cases of elevated blood lipids highlighted high-risk monogenic contributions, predominantly presenting as familial hypercholesterolemia (FH). More commonly CAD genetic risk is a function of multiple, higher frequency variants each imparting lower magnitude of risk, which can be combined to form polygenic risk scores (PRS) conveying significant risk to individuals at the extremes. However, gaps remain in clinical validation of PRSs, most notably in non-European populations. With improved and more broadly utilized genomic sequencing technologies, the genetic underpinnings of coronary artery disease are being unraveled. As a result, polygenic risk estimation is poised to become a widely used and powerful tool in the clinical setting. While the use of PRSs to augment current clinical risk stratification for optimization of cardiovascular disease risk by lifestyle change or therapeutic targeting is promising, we await adequately powered, prospective studies, demonstrating the clinical utility of polygenic risk estimation in practice.

Citing Articles

Severe multivessel coronary heart disease in a young woman with familial hypercholesterolemia and congenital heart disease: A case report.

Iqbal S, Poudel S, Huerta N, Kumar A, Shieh S, Rao S Case Rep Womens Health. 2025; 43:e00641.

PMID: 40017795 PMC: 11866166. DOI: 10.1016/j.crwh.2024.e00641.


Prevalence of genetically diagnosed familial hypercholesterolemia in Vietnamese patients with premature acute myocardial infarction.

Minh Nguyen K, Hoang S Medicine (Baltimore). 2024; 103(39):e39939.

PMID: 39331889 PMC: 11441875. DOI: 10.1097/MD.0000000000039939.


Transforming the cardiometabolic disease landscape: Multimodal AI-powered approaches in prevention and management.

Muse E, Topol E Cell Metab. 2024; 36(4):670-683.

PMID: 38428435 PMC: 10990799. DOI: 10.1016/j.cmet.2024.02.002.


rs12190287 polymorphism is related to stable angina and ST elevation myocardial infarction in a Chinese Population.

Yu T, Lee T, Tsai I, Hsuan C, Wang C, Lu Y Int J Med Sci. 2024; 21(3):483-491.

PMID: 38250610 PMC: 10797673. DOI: 10.7150/ijms.89901.


DAG1 haploinsufficiency is associated with sporadic and familial isolated or pauci-symptomatic hyperCKemia.

Traverso M, Baratto S, Iacomino M, Di Duca M, Panicucci C, Casalini S Eur J Hum Genet. 2024; 32(3):342-349.

PMID: 38177406 PMC: 10923780. DOI: 10.1038/s41431-023-01516-4.


References
1.
Li R, Chen Y, Ritchie M, Moore J . Electronic health records and polygenic risk scores for predicting disease risk. Nat Rev Genet. 2020; 21(8):493-502. DOI: 10.1038/s41576-020-0224-1. View

2.
Benn M, Watts G, Tybjaerg-Hansen A, Nordestgaard B . Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J. 2016; 37(17):1384-94. DOI: 10.1093/eurheartj/ehw028. View

3.
Lloyd-Jones D, Nam B, DAgostino Sr R, Levy D, Murabito J, Wang T . Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004; 291(18):2204-11. DOI: 10.1001/jama.291.18.2204. View

4.
Rios J, Stein E, Shendure J, Hobbs H, Cohen J . Identification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia. Hum Mol Genet. 2010; 19(22):4313-8. PMC: 2957323. DOI: 10.1093/hmg/ddq352. View

5.
Voight B, Peloso G, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen M . Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012; 380(9841):572-80. PMC: 3419820. DOI: 10.1016/S0140-6736(12)60312-2. View